Controversy

Whether BraTS-style Dice leaderboard gains translate into clinical or measurement value

Evidence grade: WEAK — Supported only by weak or preliminary evidence.

computed from the encoded evidence by the Atlas grading rule.

Position A

BraTS drove robust, near-expert automated tumor segmentation (nnU-Net etc.); enables volumetrics at scale

Position B

Marginal Dice gains are clinically meaningless; benchmark curation (skull-strip, co-registration, expert consensus labels) does not reflect messy clinical data; volumetric RANO not yet standard

Clinical stakes

Field effort concentrated on a solved-ish task while measurement standardization for trials lags

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Reviewed by Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Last updated 2026-07-01.

This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.